GlycoMimetics is a biopharmaceutical company designing and developing small molecule therapeutics to treat various cancers.
GlycoMimetics, Inc., a biopharmaceutical company, engages in the design and development of small molecule therapeutics to mimic the functions of bioactive carbohydrates. Its products include GMI-1070, a synthetic glycomimetic molecule designed to inhibit selectin types, such as E, P, and L-selectin; and GMI-1051, a small molecular weight compound for the treatment or prevention of infections caused by pseudomonas aeruginosa. The company was founded in 2003 and is based in Gaithersburg, Maryland.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Jun 23, 2006 | Series B | $15.40M | 1 | — | — | Detail |
Aug 6, 2004 | Series A | $5.10M | 1 | — | — | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
Maryland Department of Business and Economic Development | — | Series B |